PMID- 34079318
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 14
DP  - 2021
TI  - Association Between Thyroid Hormone Levels and Advanced Liver Fibrosis in 
      Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.
PG  - 2399-2406
LID - 10.2147/DMSO.S313503 [doi]
AB  - PURPOSE: To evaluate the effects of serum thyroid hormone levels on advanced 
      liver fibrosis in cases with NAFLD (non-alcoholic fatty liver disease) and T2DM 
      (type 2 diabetes mellitus). PATIENTS AND METHODS: A total of 1422 cases with T2DM 
      who were admitted to Peking University International Hospital between December 
      2014 and October 2019 were retrospectively analyzed. Standard anthropometry as 
      well as clinical and laboratory evaluation were performed on all patients. 
      Abdominal ultrasonography was performed to diagnose NAFLD. NFS (NAFLD fibrosis 
      score) was used to identify advanced fibrosis in patients with T2DM and NAFLD. 
      RESULTS: In cases with T2DM and NAFLD, the serum FT3 level in cases with advanced 
      fibrosis was lower than that in those without advanced fibrosis (4.79+/-0.89 vs 
      4.28+/-1.19, P < 0.05), and significant difference was not found in serum levels of 
      FT4 and TSH between cases with advanced fibrosis and those without advanced 
      fibrosis (P > 0.05). The incidence of advanced fibrosis declined as the rise of 
      serum FT3 levels (P (trend) < 0.05). Besides, FT3 (OR, 0.492; 95% CI, 
      0.384-0.631) was noted as a factor influencing advanced fibrosis in cases with 
      T2DM and NAFLD (P< 0.05). CONCLUSION: In cases with T2DM and NAFLD, the incidence 
      of advanced fibrosis is negatively correlated with serum FT3 levels, and a low 
      FT3 level is an independent risk factor of advanced fibrosis.
CI  - (c) 2021 Du et al.
FAU - Du, Jing
AU  - Du J
AUID- ORCID: 0000-0003-3909-9397
AD  - Department of Endocrinology, Peking University International Hospital, Beijing, 
      People's Republic of China.
FAU - Chai, Sanbao
AU  - Chai S
AUID- ORCID: 0000-0002-8746-518X
AD  - Department of Endocrinology, Peking University International Hospital, Beijing, 
      People's Republic of China.
FAU - Zhao, Xin
AU  - Zhao X
AD  - Department of Endocrinology, Peking University International Hospital, Beijing, 
      People's Republic of China.
FAU - Sun, Jianbin
AU  - Sun J
AUID- ORCID: 0000-0002-4861-1738
AD  - Department of Endocrinology, Peking University International Hospital, Beijing, 
      People's Republic of China.
FAU - Zhang, Xiaomei
AU  - Zhang X
AD  - Department of Endocrinology, Peking University International Hospital, Beijing, 
      People's Republic of China.
FAU - Huo, Lili
AU  - Huo L
AD  - Department of Endocrinology, Beijing Jishuitan Hospital, Beijing, People's 
      Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210526
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC8165094
OTO - NOTNLM
OT  - advanced fibrosis
OT  - diabetes mellitus
OT  - non-alcoholic fatty liver disease
OT  - thyroid hormone
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/06/04 06:00
MHDA- 2021/06/04 06:01
PMCR- 2021/05/26
CRDT- 2021/06/03 06:37
PHST- 2021/03/30 00:00 [received]
PHST- 2021/05/11 00:00 [accepted]
PHST- 2021/06/03 06:37 [entrez]
PHST- 2021/06/04 06:00 [pubmed]
PHST- 2021/06/04 06:01 [medline]
PHST- 2021/05/26 00:00 [pmc-release]
AID - 313503 [pii]
AID - 10.2147/DMSO.S313503 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2021 May 26;14:2399-2406. doi: 10.2147/DMSO.S313503. 
      eCollection 2021.